secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0000939767-26-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q1 revenue $610.8M, GAAP EPS $0.79; announces $750M buyback
--------------------------------------------------------------------

- Total revenues $610.8M (+10% YoY); cabozantinib U.S. net product revenue $555.0M.
- GAAP diluted EPS $0.79 (vs. $0.55 in Q1 2025); non-GAAP diluted EPS $0.87.
- Board authorized new $750M stock repurchase program through Dec 31, 2027.
- Zanzalintinib NDA accepted for colorectal cancer; PDUFA target Dec 3, 2026.
- Company plans to complete current $750M buyback this month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/0000939767-26-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel-20260505.htm
  HTML page:      https://secwatch.observer/filing/0000939767-26-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer